ETS Transcription Factors Control Transcription of EZH2 and Epigenetic Silencing of the Tumor Suppressor Gene Nkx3.1 in Prostate Cancer
Open Access
- 10 May 2010
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (5), e10547
- https://doi.org/10.1371/journal.pone.0010547
Abstract
ETS transcription factors regulate important signaling pathways involved in cell differentiation and development in many tissues and have emerged as important players in prostate cancer. However, the biological impact of ETS factors in prostate tumorigenesis is still debated. We performed an analysis of the ETS gene family using microarray data and real-time PCR in normal and tumor tissues along with functional studies in normal and cancer cell lines to understand the impact in prostate tumorigenesis and identify key targets of these transcription factors. We found frequent dysregulation of ETS genes with oncogenic (i.e., ERG and ESE1) and tumor suppressor (i.e., ESE3) properties in prostate tumors compared to normal prostate. Tumor subgroups (i.e., ERGhigh, ESE1high, ESE3low and NoETS tumors) were identified on the basis of their ETS expression status and showed distinct transcriptional and biological features. ERGhigh and ESE3low tumors had the most robust gene signatures with both distinct and overlapping features. Integrating genomic data with functional studies in multiple cell lines, we demonstrated that ERG and ESE3 controlled in opposite direction transcription of the Polycomb Group protein EZH2, a key gene in development, differentiation, stem cell biology and tumorigenesis. We further demonstrated that the prostate-specific tumor suppressor gene Nkx3.1 was controlled by ERG and ESE3 both directly and through induction of EZH2. These findings provide new insights into the role of the ETS transcriptional network in prostate tumorigenesis and uncover previously unrecognized links between aberrant expression of ETS factors, deregulation of epigenetic effectors and silencing of tumor suppressor genes. The link between aberrant ETS activity and epigenetic gene silencing may be relevant for the clinical management of prostate cancer and design of new therapeutic strategies.Keywords
This publication has 47 references indexed in Scilit:
- Recurrent gene fusions in prostate cancerNature Reviews Cancer, 2008
- Deletion, Methylation, and Expression of the NKX3.1 Suppressor Gene in Primary Human Prostate CancerCancer Research, 2005
- Androgen-Induced Differentiation and Tumorigenicity of Human Prostate Epithelial CellsCancer Research, 2004
- Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27Genes & Development, 2004
- The ETS Transcription Factor ESE-1 Transforms MCF-12A Human Mammary Epithelial Cells via a Novel Cytoplasmic MechanismMolecular and Cellular Biology, 2004
- Ets proteins in biological control and cancerJournal of Cellular Biochemistry, 2004
- ESX induces transformation and functional epithelial to mesenchymal transition in MCF-12A mammary epithelial cellsOncogene, 2004
- EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancerThe EMBO Journal, 2003
- Selective inhibition of transcription of the Ets2 gene in prostate cancer cells by a triplex-forming oligonucleotideNucleic Acids Research, 2003
- The ETS-domain transcription factor familyNature Reviews Molecular Cell Biology, 2001